Group items tagged

The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.

To date one long-term study indicates a treatment success rate of 78%-81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC - surgical excision.

Superficial Basal Cell Carcinoma Aldara™ cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.  The histological diagnosis of superficial basal cell carcinoma should be established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.

Mohs micrographic surgery is also indicated for the treatment of the following: ~Tumors with histopathologic features showing morpheaform or sclerotic patterns. ~Tumors arising in regions where maximum preservation of uninvolved tissue is desirable 

Clinical studies have reported that oral fish oil supplementation has beneficial effects in rheumatoid arthritis and among some patients with asthma, supporting the idea that the n-3 PUFA in fish oil are anti-inflammatory. There are indications that inclusion of n-3 PUFA in enteral and parenteral formulas might be beneficial to patients in intensive care or post-surgery.

Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.\nBecker Y.\nAnticancer Res. 2006 Mar-Apr;26(2A):1113-34. Review.\nPMID: 16619514 \n\nPolarized Th1 cells produce interleukin (IL)-2, IL-12 and interferon (IFN)-gamma, and polarized Th2 cells and the hematopoietic cells produce IL-4, IL-5, IL-6, IL-10 and IL-13. In healthy individuals there is a Th1/Th2 cytokine balance, but during microbial-induced inflammation the pathogens induce an overproduction of the Th2 cytokines that inhibit the adaptive immune response against the pathogen. A review of studies on the Th1/Th2 cytokine balance in humans harboring different tumor types revealed that tumor cells induce increased Th2 cytokine levels in patients' sera that can serve as indicators for the existence of tumors. I\n

Natural Standard Herbal Pharmacotherapy: An Evidence-Based Approach is now available for purchase. The book provides practical guidance on the use of herbal therapies for medical conditions. This reference tool will be an essential part of herbal pharmacy core curricula for all healthcare disciplines. Chapters are organized by medical condition and present supportive evidence, including potential mechanisms of action and dosing, for selected herbal therapies. The chapters also include integrative therapy plans to help clinicians quickly assess patient needs and create cohesive treatment plans. In addition, adjunct therapies, including herbs, supplements and modalities, that are commonly used in combination with primary treatments are discussed. Case studies, which summarize efficacy, safety, dosing and interactions for high-utilization products, help prepare healthcare providers for patient counseling in clinical practice. Review questions, similar to those on national board exams, allow readers to evaluate their learning and identify areas for further study. The book also includes several appendices, which provide information about lab values as well as the safety, interactions and pharmacokinetics of select herbs.